In continuation of my update
docetaxel
"Pertuzumab plus trastuzumab and docetaxel has competitive advantages
in efficacy over our current proprietary clinical gold-standard
treatment, trastuzumab plus docetaxel," said Decision Resources Analyst
Amy Duva"l.
Decision Resources' analysis of the breast cancer
drug market also finds that Roche/Genentech/Chugai's Trastuzumab-DM1
(T-DM1) is likely to initially enter later-lines of treatment before
receiving approval for the first-line setting, which means it will gain
use across all lines of therapy, fragmenting its patient share across
lines of treatment and restricting its uptake in the first-line setting.
Additionally, according to insights from interviewed thought-leaders, pertuzumab plus trastuzumab and docetaxel
and T-DM1 plus pertuzumab have demonstrated the potential to increase
patients' overall survival, which has not been improved by
drug-treatment since the approval of trastuzumab over a decade ago.
Findings also reveal that the overall breast cancer drug market
declined from $10 billion in 2010 to $9.3 billion in 2011 in the United
States, France, Germany, Italy, Spain, the United Kingdom and Japan.
Decision Resources forecasts that the market will increase from $9.3
billion in 2011 to $10.8 billion in 2020. Significant declines in sales,
due to generic and biosimilar price erosion and a substantial reduction
in the prescribing of Roche/Genentech/Chugai's Avastin,
particularly in the U.S., will be offset by the launch and uptake of
premium-priced emerging therapies, particularly in the metastatic
HER2-positive setting.
Ref : http://decisionresources.com/News-and-Events/Press-Releases/Breast-Cancer-Drug-Market-020212
